3-[(3-Amino-4-methylaminobenzoyl)pyridin-2-ylamino]propionic acid ethyl ester
[CAS# 212322-56-0]

Identification

• Classification: Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Pyridine compound >> Pyridine derivative
• Name: 3-[(3-Amino-4-methylaminobenzoyl)pyridin-2-ylamino]propionic acid ethyl ester
• Synonyms: ethyl 3-[[3-amino-4-(methylamino)benzoyl]-pyridin-2-ylamino]propanoate
• Molecular Formula: C₁₈H₂₂N₄O₃
• Molecular Weight: 342.39
• CAS Registry Number: 212322-56-0
• EC Number: 606-728-0
• SMILES: CCOC(=O)CCN(C1=CC=CC=N1)C(=O)C2=CC(=C(C=C2)NC)N

Properties

• Density: 1.3±0.1 g/cm³, Calc.^*
• Index of Refraction: 1.640, Calc.^*
• Boiling Point: 576.2±50.0 °C (760 mmHg), Calc.^*
• Flash Point: 302.2±30.1 °C, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302-H315-H319-H332-H335
• Safety Statements: P261-P280-P305+P351+P338

Discovery and Applications

3-[(3-Amino-4-methylaminobenzoyl)pyridin-2-ylamino]propionic acid ethyl ester is a complex organic compound with significant potential in the field of medicinal chemistry. This compound features a combination of functional groups, including an amino group, a methyl group, a benzoyl group, a pyridine ring, and an ethyl ester, each contributing to the overall molecular activity and reactivity. The presence of both amino and ester groups, as well as the aromatic components, suggests that this compound could interact with various biological targets, particularly enzymes and receptors involved in cellular processes.

The discovery of 3-[(3-Amino-4-methylaminobenzoyl)pyridin-2-ylamino]propionic acid ethyl ester is part of a broader effort to develop new molecules that can effectively modulate enzyme activity or receptor function. The pyridine ring in the structure is known for its ability to interact with proteins and enzymes in biological systems, often contributing to the compound's binding affinity. The amino and methyl groups provide further functional versatility, potentially enhancing the molecule's activity and selectivity for its target.

One of the main areas of application for this compound is in enzyme inhibition. The combination of the pyridine ring with the benzoyl and amino groups makes this molecule well-suited to interacting with enzymes involved in metabolic processes or signaling pathways. By modulating the activity of these enzymes, the compound could play a role in treating diseases where enzyme dysregulation is a key factor, such as in cancer, inflammation, or metabolic disorders.

The ethyl ester group present in the compound further enhances its potential for pharmaceutical applications. Esters are often employed to improve the solubility and bioavailability of compounds, enabling more efficient absorption and distribution in the body. This makes 3-[(3-Amino-4-methylaminobenzoyl)pyridin-2-ylamino]propionic acid ethyl ester a promising candidate for development as a drug, as it may offer favorable pharmacokinetic properties.

Additionally, the compound's unique structure could make it useful in neurological research. The combination of the pyridine and amino groups suggests that it may interact with neurotransmitter systems, making it a potential candidate for the treatment of neurological diseases. Further investigation into its effects on neurotransmitter receptors could reveal its potential in conditions such as Alzheimer's disease, Parkinson's disease, or other neurodegenerative disorders.

In summary, 3-[(3-Amino-4-methylaminobenzoyl)pyridin-2-ylamino]propionic acid ethyl ester is a promising compound in the field of medicinal chemistry. Its complex structure, including key functional groups like the pyridine ring, amino group, and ethyl ester, suggests potential applications in enzyme inhibition, receptor modulation, and possibly neurological diseases. Ongoing research into its biological activity and therapeutic potential will be crucial in determining its suitability for clinical use.

References

2024. Synthesis of deuterium labeled dabigatran etexilate. *Journal of Radioanalytical and Nuclear Chemistry*, 333(7).
DOI: 10.1007/s10967-024-09584-6

2019. Synthesis, Crystal Structure, and Anti-Gastric Cancer Activity of Ethyl 3-(3-Amino-4-(Methylamino)-N-(Pyridin-2-Yl) Benzamido)Propanoate. *Journal of Structural Chemistry*, 60(12).
DOI: 10.1134/s0022476619120187

2008. Dabigatran etexilate. *Pharmaceutical Substances*.
URL: KD-04-0169